Deregulation of microRNA expression in thyroid tumors

Journal of Zhejiang University: Science B

Volumn 15, Issue 3, 2014, Pages 212-224

  Yuan, Zi Ming ^a   Yang, Zhi Li ^a   Zheng, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

MicroRNA; Single nucleotide polymorphism (SNP); Somatic mutation; Target gene; Thyroid tumor

Indexed keywords

MICRORNA;

ANAPLASTIC THYROID CANCER; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; METASTASIS; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID TUMOR; TUMOR GENE; TUMOR INVASION;

CARCINOMA; CARCINOMA, PAPILLARY, FOLLICULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID NEOPLASMS;

EID: 84897063289     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1300192     Document Type: Review

References (92)

1. Abraham, D., Jackson, N., Gundara, J.S., et al., 2011. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin. Cancer Res., 17(14):4772-4781. [doi:10.1158/1078-0432.CCR-11-0242]
2. Agretti, P., Ferrarini, E., Rago, T., et al., 2012. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur. J. Endocrinol., 167(3):393-400. [doi:10.1530/EJE-12-0400]
3. Ambros, V., 2004. The functions of animal microRNAs. Nature, 431(7006):350-355. [doi:10.1038/nature02871] (Pubitemid 39265675)
4. Argraves, W.S., Greene, L.M., Cooley, M.A., et al., 2003. Fibulins: physiological and disease perspectives. EMBO Rep., 4(12):1127-1131. [doi:10.1038/sj.embor.7400033] (Pubitemid 38088406)
5. Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2):281-297. [doi:10.1016/S0092-8674(04)00045-5]
6. Bhaumik, D., Scott, G.K., Schokrpur, S., et al., 2008. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 27(42):5643-5647. [doi:10.1038/onc.2008.171]
7. Boucheix, C., Duc, G.H., Jasmin, C., et al., 2001. Tetraspanins and malignancy. Expert Rev. Mol. Med., 3(4):1-17. [doi:10.1017/S1462399401002381]
8. Braun, J., Hüttelmaier, S., 2011. Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res., 4(Suppl. 1):S1. [doi:10.1186/1756-6614-4-S1-S1]
9. Braun, J., Hoang-Vu, C., Dralle, H., et al., 2010. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene, 29(29):4237-4244. [doi:10.1038/onc.2010.169]
10. Cameron, J.E., Yin, Q., Fewell, C., et al., 2008. Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. J. Virol., 82(4):1946-1958. [doi:10.1128/JVI. 02136-07] (Pubitemid 351206940)
11. Carraro, G., El-Hashash, A., Guidolin, D., et al., 2009. miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-cadherin distribution. Dev. Biol., 333(2):238-250. [doi:10.1016/j.ydbio.2009.06.020]
12. Castellone, M.D., Guarino, V., de Falco, V., et al., 2004. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene, 23(35):5958-5967. [doi:10.1038/sj.onc.1207790] (Pubitemid 39093540)
13. Chen, Y.T., Kitabayashi, N., Zhou, X.K., et al., 2008. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol., 21(9):1139-1146. [doi:10.1038/modpathol.2008.105]
14. Chiappetta, G., Ferraro, A., Vuttariello, E., et al., 2008. HMGA2 mRNA expression correlates with the malignant phenotypein human thyroid neoplasias. Eur. J. Cancer, 44(7):1015-1021. [doi:10.1016/j.ejca.2008.02.039]
15. Chin, L., Hahn, W.C., Getz, G., et al., 2011. Making sense of cancer genomic data. Genes Dev., 25(6):534-555. [doi:10.1101/gad.2017311]
16. V600E mutation. Thyroid, 20(5):489-494. [doi:10.1089/thy.2009.0027]
17. Ciafrè, S.A., Galardi, S., Mangiola, A., et al., 2005. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biopys. Res. Commun., 334(4):1351-1358. [doi:10.1016/j.bbrc.2005.07.030] (Pubitemid 41074723)
18. Colamaio, M., Borbone, E., Russo, L., et al., 2011. miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J. Clin. Endocrinol. Metab., 96(12):E1915-E1924. [doi:10.1210/jc. 2011-0408]
19. Cowland, J.B., Hother, C., Grønbaek, K., 2007. MicroRNAs and cancer. APMIS, 115(10):1090-1106. [doi:10.1111/j.1600-0463.2007.apm-775.xml.x] (Pubitemid 350179476)
20. Dean, D.S., Gharib, H., 2008. Epidemiology of thyroid nodules. Best Pract. Res. Clin. Endocrinol. Metab., 22(6):901-911. [doi:10.1016/j.beem.2008. 09.019]
21. V600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab., 93(10):3943-3949. [doi:10.1210/jc.2008-0607]
22. Elisei, R., Cosci, B., Romei, C., et al., 2008b. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab., 93(3):682-687. [doi:10.1210/jc.2007-1714] (Pubitemid 351398539)
23. Esposito, F., Tornincasa, M., Pallante, P., et al., 2012. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J. Clin. Endocrinol. Metab., 97(5):E710-E718. [doi:10.1210/jc.2011-3068]
24. Fagin, J.A., Mitsiades, N., 2008. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metab., 22(6):955-969. [doi:10.1016/j.beem.2008.09.017]
25. Felli, N., Fontana, L., Pelosi, E., et al., 2005. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. PNAS, 102(50):18081-18086. [doi:10.1073/pnas.0506216102] (Pubitemid 41798505)
26. Ferraz, C., Eszlinger, M., Paschke, R., 2011. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J. Clin. Endocrinol. Metab., 96(7):2016-2026. [doi:10.1210/jc.2010- 2567]
27. Frezzetti, D., Reale, C., Calì, G., et al., 2011a. The microRNA-processing enzyme Dicer is essential for thyroid function. PLoS ONE, 6(11):e27648. [doi:10.1371/journal.pone.0027648]
28. Frezzetti, D., de Menna, M., Zoppoli, P., et al., 2011b. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene, 30(3):275-286. [doi:10.1038/onc.2010.416]
29. Galardi, S., Mercatelli, N., Giorda, E., et al., 2007. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem., 282(32):23716-23724. [doi:10.1074/jbc.M701805200] (Pubitemid 47311902)
30. Gallagher, W.M., Greene, L.M., Ryan, M.P., et al., 2001. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett., 489(1):59-66. [doi:10.1016/S0014-5793(00)02389-9] (Pubitemid 32176006)
31. Gao, Y., Wang, C., Shan, Z., et al., 2010. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr. J., 57(1):81-86. [doi:10.1507/endocrj.K09E-220]
32. Garofalo, M., Quintavalle, C., di Leva, G., et al., 2008. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 27(27):3845-3855. [doi:10.1038/onc.2008.6] (Pubitemid 351862062)
33. Garzia, L., Andolfo, I., Cusanelli, E., et al., 2009. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE, 4(3): e4998. [doi:10.1371/journal.pone.0004998]
34. Gebeshuber, C.A., Zatloukal, K., Martinez, J., 2009. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep., 10(4): 400-405. [doi:10.1038/embor.2009.9]
35. Geraldo, M.V., Yamashita, A.S., Kimura, E.T., 2012. Micro-RNA miR-146b-5p regulates signal transduction of TGF-â by repressing SMAD4 in thyroid cancer. Oncogene, 31(15):1910-1922. [doi:10.1038/onc.2011.381]
36. Gharib, H., 2004. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr. Pract., 10(1): 31-39. [doi:10.4158/EP.10.1.31]
37. Gregory, P.A., Bracken, C.P., Bert, A.G., et al., 2008. Micro-RNAs as regulators of epithelial-mesenchymal transition. Cell Cycle, 7(20):3112-3118.
38. Guo, C.J., Pan, Q., Li, D.G., et al., 2009. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J. Hepatol., 50(4):766-778. [doi:10.1016/j.jhep.2008.11.025]
39. He, H., Jazdzewski, K., Li, W., et al., 2005. The role of microRNA genes in papillary thyroid carcinoma. PNAS, 102(52):19075-19080. [doi:10.1073/pnas. 0509603102] (Pubitemid 43049568)
40. Huang, Y., Shen, X.J., Zou, Q., et al., 2010. Biological functions of microRNAs: a review. J. Physiol. Biochem., 67(1):129-139. [doi:10.1007/s13105- 010-0050-6]
41. Hurst, D.R., Edmonds, M.D., Scott, G.K., et al., 2009. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res., 69(4):1279-1283. [doi:10.1158/0008-5472.CAN-08-3559]
42. Jazdzewski, K., Murray, E.L., Franssila, K., et al., 2008. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. PNAS, 105(20):7269-7274. [doi:10.1073/pnas.0802682105] (Pubitemid 351754467)
43. Knauf, J.A., Ma, X., Smith, E.P., et al., 2005. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res., 65(10):4238-4245. [doi:10.1158/0008-5472.CAN-05-0047] (Pubitemid 40775662)
44. Kondo, T., Ezzat, S., Asa, S.L., 2006. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer, 6(4):292-306. [doi:10.1038/ nrc1836]
45. Korpal, M., Kang, Y., 2008. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol., 5(3):115-119.
46. Kota, J., Chivukula, R.R., O'Donnell, K.A., et al., 2009. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6):1005-1017. [doi:10.1016/j.cell.2009.04.021]
47. Ku, G., McManus, M.T., 2008. Behind the scenes of a small RNA gene-silencing pathway. Hum. Gene Ther., 19(1):17-26. [doi:10.1089/hum.2007. 1226] (Pubitemid 351171379)
48. Labbaye, C., Spinello, I., Quaranta, M.T., et al., 2008. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat. Cell Biol., 10(7):788-801. [doi:10.1038/ncb1741] (Pubitemid 351927708)
49. Landi, D., Gemignani, F., Landi, S., 2012. Role of variations within microRNA-binding sites in cancer. Mutagenesis, 27(2):205-210. [doi:10.1093/mutage/ger055]
50. Leone, V., D'Angelo, D., Rubio, I., et al., 2011. miR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1α. J. Clin. Endocrinol. Metab., 96(9):E1388-E1398. [doi:10.1210/jc.2011-0345]
51. Liu, X., Cheng, Y., Yang, J., et al., 2012. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J. Mol. Cell. Cardiol., 52(1):245-255. [doi:10.1016/j.yjmcc.2011.11.008]
52. Marini, F., Luzi, E., Brandi, M.L., 2011. MicroRNA role in thyroid cancer development. J. Thyroid Res., 2011: 407123. [doi:10.4061/2011/407123]
53. Mattie, M.D., Benz, C.C., Bowers, J., et al., 2006. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer, 5(1):24. [doi:10.1186/1476-4598-5-24]
54. Mazeh, H., 2012. MicroRNA as a diagnostic tool in fine-needle aspiration biopsy of thyroid nodules. Oncologist, 17(8):1032-1038. [doi:10.1634/ theoncologist.2012-0013]
55. McHenry, C.R., Phitayakorn, R., 2011. Follicular adenoma and carcinoma of the thyroid gland. Oncologist, 16(5):585-593. [doi:10.1634/theoncologist.2010- 0405]
56. Menon, M.P., Khan, A., 2009. micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J. Clin. Pathol., 62(11):978-985. [doi:10.1136/jcp.2008.063909]
57. Mian, C., Pennelli, G., Fassan, M., et al., 2012. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid, 22(9):890-896. [doi:10.1089/thy.2012.0045]
58. Mitomo, S., Maesawa, C., Ogasawara, S., et al., 2008. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci., 99(2):280-286. [doi:10.1111/j.1349-7006.2007.00666.x] (Pubitemid 351228481)
59. V600E in thyroid carcinoma: therapeutic implications. Mol. Cancer Ther., 6(3):1070-1078. [doi:10.1158/1535-7163.MCT-06-0449]
60. Murakami, Y., Yasuda, T., Saigo, K., et al., 2006. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 25(17):2537-2545. [doi:10.1038/sj.onc.1209283]
61. Nikiforov, Y.E., Nikiforova, M.N., 2011. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol., 7 (10):569-580. [doi:10.1038/nrendo. 2011.142]
62. Nikiforova, M.N., Tseng, G.C., Steward, D., et al., 2008. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab., 93(5):1600-1608. [doi:10.1210/jc.2007- 2696] (Pubitemid 351656494)
63. Nikiforova, M.N., Chiosea, S.I., Nikiforov, Y.E., 2009. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol., 20(2):85-91. [doi:10.1007/s12022-009-9069-z]
64. Pallante, P., Visone, R., Croce, C.M., et al., 2010. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr. Relat. Cancer, 17(1):91-104. [doi:10.1677/ERC-09-0217]
65. Ponta, H., Hofmann, M., Herrlich, P., 2001. Recent advances in the genetics of metastasis. Eur. J. Cancer, 30A(13):1995-2001.
66. Ricarte-Filho, J.C., Fuziwara, C.S., Yamashita, A.S., et al., 2009. Effects of let-7 microRNA on cell growth and differentiation of papillary thyroid cancer. Transl. Oncol., 2(4):236-241.
67. Schulte, K.M., Jonas, C., Krebs, R., et al., 2001. Activin A and activin receptors in thyroid cancer. Thyroid, 11(1):3-14. [doi:10.1089/ 10507250150500603] (Pubitemid 32127406)
68. Schwertheim, S., Sheu, S.Y., Worm, K., et al., 2009. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm. Metab. Res., 41(6):475-481. [doi:10.1055/s-0029-1215593]
69. Shastry, B.S., 2009. SNPs: impact on gene function and phenotype. In: Komar, A.A. (Ed.), Single Nucleotide Polymorphisms. Springer, p.3-22. [doi:10.1007/978-1-60327-411-1-1]
70. Sheu, S.Y., Grabellus, F., Schwertheim, S., et al., 2010. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br. J. Cancer, 102(2):376-382. [doi:10.1038/sj.bjc.6605493]
71. Shibru, D., Chung, K.W., Kebebew, E., 2008. Recent developments in the clinical application of thyroid cancer biomarkers. Curr. Opin. Oncol., 20(1):13-18. [doi:10.1097/CCO.0b013e3282f27e49] (Pubitemid 350190976)
72. Taganov, K.D., Boldin, M.P., Chang, K.J., et al., 2006. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. PNAS, 103(33):12481-12486. [doi:10.1073/pnas.0605298103] (Pubitemid 44267285)
73. Takakura, S., Mitsutake, N., Nakashima, M., et al., 2008. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci., 99(6):1147-1154. [doi:10.1111/j.1349-7006.2008.00800.x] (Pubitemid 351676626)
74. Tetzlaff, M.T., Liu, A., Xu, X., et al., 2007. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr. Pathol., 18(3):163-173. [doi:10.1007/s12022-007-0023-7] (Pubitemid 351384379)
75. Visone, R., Pallante, P., Vecchione, A., et al., 2007. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 26(54):7590-7595. [doi:10.1038/sj.onc.1210564] (Pubitemid 350207711)
76. Vriens, M.R., Schreinemakers, J.M., Suh, I., et al., 2009. Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol., 5(8):1283-1293. [doi:10.2217/fon.09.85]
77. Vriens, M.R., Weng, J., Suh, I., et al., 2012. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer, 118(13):3426-3432. [doi:10.1002/cncr.26587]
78. Wan, P.T., Garnett, M.J., Roe, S.M., et al., 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 116(6):855-867. [doi:10.1016/S0092-8674(04)00215-6] (Pubitemid 38410730)
79. Wang, J., Wang, Q., Liu, H., et al., 2012. The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis, 27(6):779-788. [doi:10.1093/mutage/ ges052]
80. Weber, F., Teresi, R.E., Broelsch, C.E., et al., 2006. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab., 91(9):3584-3591. [doi:10.1210/jc.2006-0693] (Pubitemid 44402141)
81. Wellbrock, C., Karasarides, M., Marais, R., 2004. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol., 5(11):875-885. [doi:10.1038/nrm1498] (Pubitemid 39486539)
82. Wlazlinski, A., Engers, R., Hoffmann, M.J., et al., 2007. Downregulation of several fibulin genes in prostate cancer. Prostate, 67(16):1770-1780. [doi:10.1002/pros.20667] (Pubitemid 350228729)
83. Wojciechowska, K., Lewinski, A., 2006. BRAF mutations in papillary thyroid carcinoma. Endocr. Regul., 40(4): 129-138. (Pubitemid 46045518)
84. Xing, M., 2007. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev., 28(7):742-762. [doi:10.1210/er.2007-0007] (Pubitemid 350294294)
85. Xiong, Y., Zhang, L., Holloway, A.K., et al., 2011. miR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS ONE, 6(10):e24717. [doi:10.1371/journal.pone.0024717]
86. Yau, T., Lo, C.Y., Epstein, R.J., et al., 2008. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann. Surg. Oncol., 15(9):2500-2505. [doi:10.1245/s10434-008-0005-0]
87. Yip, L., Nikiforova, M.N., Carty, S.E., et al., 2009. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 146(6):1215-1223. [doi:10.1016/j.surg.2009.09.011]
88. Yip, L., Kelly, L., Shuai, Y., et al., 2011. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol., 18(7):2035-2041. [doi:10.1245/s10434-011-1733-0]
89. Yu, S., Liu, Y., Wang, J., et al., 2012. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 97(6):2084-2092. [doi:10.1210/jc.2011-3059]
90. Yue, C., Wang, M., Ding, B., et al., 2011. Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. Gynecol. Oncol., 122(1):33-37. [doi:10.1016/j.ygyno.2011.03.032]
91. Zhou, B., Wang, K., Wang, Y., et al., 2011. Common genetic polymorphisms in pre-microRNAs and risk of cervical squamous cell carcinoma. Mol. Carcinog., 50(7):499-505. [doi:10.1002/mc.20740]
92. Zhu, H., Wu, H., Liu, X., et al., 2009. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy, 5(6):816-823.